Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > BUSINESS
BUSINESS
- Medipal, Mitsubishi Acquire Shares in Chinese Pharma Wholesaler for 8 Billion Yen
July 30, 2013
- Janssen Files NDA for Prostate Cancer Treatment Abiraterone in Japan
July 30, 2013
- Kyowa Kirin’s 1st Half Sales Up 2.1%, but Mainstay Nesp Slumps 7%
July 29, 2013
- Interim Analysis of Multinational PIII Study of Orteronel Shows No Improvement of OS in Patients with mCRPC: Takeda
July 29, 2013
- Bell Medical, inVentiv to Provide Promotion and PMS Support Services
July 26, 2013
- Chugai Sales Up 8.4% Due to Increase in Cancer Treatment, Overseas Sales
July 26, 2013
- Safety of Atopic Dermatitis Treatment Confirmed in PI Study in Japan: AnGes MG
July 26, 2013
- OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines
July 26, 2013
- Can Generic Drug Industry Achieve “Zero Supply Disruptions” by FY2015? 30 Products –Largest Ever– from 14 Companies Experience Shortage in 2012
July 26, 2013
- Toho Pharmaceutical’s New Logistics Center in Hyogo Begins Operations
July 25, 2013
- Janssen Provides Free Simplified Dementia Screening Tool to Medical Institutions
July 25, 2013
- Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
- Novartis Launches Diovan OD Tablets, Sales Reps Find Promotion Difficult
July 24, 2013
- Astagraf XL, Tacrolimus Extended-Release Capsules, Approved in US: Astellas
July 24, 2013
- Kyowa Kirin Files Poteligeo for PTCL, CTCL in Japan
July 23, 2013
- Toho University Prof. Nakamura Says Prasugrel Promising in Preventing Platelet Clotting
July 22, 2013
- AD Treatment Lu AE58054 Improves Cognitive Performance in PII Study: Otsuka Pharmaceutical
July 22, 2013
- AD Biomarker TOMM40 Favorable in Detecting AD Risk: Takeda
July 19, 2013
- Xtandi Share May Increase as Second-Line Drug in US, Ranks Top as Third-Line Drug: Kantar Health
July 19, 2013
- Teribone’s Sales Growing Fast, Owing to High Demand of Drugs Promoting Bone Formation: Asahi Kasei Pharma President
July 19, 2013
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…